Research

Hormonal

Treatment with combined naltrexone-sustained release (32 mg) and bupropion-sustained release (360 mg) (NB32) attenuates hypothalamic brain reactivity to food cues while enhancing activation in regions responsible for self-control, memory, and interoception.

If you struggle with intense food cravings or lack of satiety signals, this medication (NB32) may help by reducing the brain's 'pull' towards food cues and enhancing your ability to use self-control and awareness of fullness. It is not a magic bullet but works by changing how your brain processes food signals. Consult a doctor to see if you are a candidate, as side effects can occur.

GoodSupportsHIGH confidence
NB32 attenuated the activation in the hypothalamus in response to food cues (P<0.01), it enhanced activation in regions involved in inhibitory control (anterior cingulate), internal awareness (superior frontal, insula, superior parietal) and memory (hippocampal) regions (whole-brain analysis; P<0.05).
G-J Wang et al. · International Journal of Obesity · 2013

Why this rating

Randomized controlled trial with fMRI outcomes, though short duration (4 weeks) and small sample size (n=40).

Source

Effect of combined naltrexone and bupropion therapy on the brain’s reactivity to food cues

G-J Wang et al. · International Journal of Obesity · 2013

DOI 10.1038/ijo.2013.145

rct · n=40Cited 242×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →